Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines

Clinical and Vaccine Immunology

Volumn 19, Issue 10, 2012, Pages 1633-1640

  Fox, Christopher B ^a   Baldwin, Susan L ^a   Vedvick, Thomas S ^a   Angov, Evelina ^b   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT AQUEOUS NANOPARTICLE SUSPENSION FORMULATION; GLUCOPYRANOSYL LIPID ADJUVANT SQUALENE BASED STABLE EMULSION; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; MALARIA VACCINE; MONTANIDE ISA 720; PLASMODIUM FALCIPARUM CELL TRAVERSAL PROTEIN FOR OOKINETES AND SPOROZOITES; SQUALENE; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SECRETING PLASMA CELL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NANOEMULSION; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; EMULSIONS; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MALARIA VACCINES; MANNITOL; MICE; MICE, INBRED BALB C; NANOPARTICLES; OLEIC ACIDS; PLASMODIUM FALCIPARUM; SQUALENE; TH1 CELLS; TOLL-LIKE RECEPTOR 4; VACCINES, SYNTHETIC;

EID: 84867239659     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00235-12     Document Type: Article

References (29)

1. Anderson RC, et al. 2010. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B Biointerfaces 75:123-132.
2. Arias MA, et al. 2012. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 7:e41144. doi:10.1371/journal.pone.0041144.
3. Baldwin SL, et al. 2009. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27:3063-3071.
4. Baldwin SL, et al. 2012. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 188:2189-2197.
5. Baldwin SL, et al. 2009. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27:5956-5963.
6. Baudner BC, et al. 2009. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26:1477-1485.
7. Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse C, Angov E. 2011. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine 29:5940-5949.
8. Bergmann-Leitner ES, et al. 2010. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS One 5:e12294. doi:10.1371/journal.pone.0012294.
9. Cioppa GD, Vesikari T, Sokal E, Lindert K, Nicolay U. 2011. Trivalent and quadrivalent MF59-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine 29:8696-8704.
10. Coler RN, et al. 2010. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5:e13677. doi:10.1371/ journal.pone.0013677.
11. Coler RN, et al. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6:e16333. doi:10.1371/journal.pone.0016333.
12. Della Cioppa G, et al. 2012. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 adjuvant: results from a dose-finding clinical trial in older adults. Hum. Vaccine Immunother. 8:216-227.
13. Fox CB. 2009. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14:3286-3312.
14. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. 2011. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 29:9563-9572.
15. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. 2012. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS PharmSciTech 13:498-506.
16. Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221:35-41. (Pubitemid 29017921)
17. Gao N, Dang T, Yuan D. 2001. IFN-γ-dependent and-independent initiation of switch recombination by NK cells. J. Immunol. 167:2011-2018. (Pubitemid 32747508)
18. Hibbert DB, Gooding JJ. 2006. Data analysis for chemistry. Oxford University Press, New York, NY.
19. Ioannou XP, et al. 2002. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21:127-137. (Pubitemid 35351359)
20. Keitel W, et al. 2010. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28:840-848.
21. Langley JM, et al. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J. Infect. Dis. 201:1644-1653.
22. Lin Y, et al. 2009. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31:799-810.
23. Markine-Goriaynoff D, et al. 2000. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int. Immunol. 12:223-230. (Pubitemid 30088315)
24. Mosca F, et al. 2008. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 105:10501-10506.
25. Ott G, et al. 1995. MF59: design and evaluation of a safe and potent adjuvant for human vaccines, p 277-296. In Powell MF, Newman MJ (ed), Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, NY.
26. Owusu-Agyei S, et al. 2009. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One 4 : e7302. doi:10.1371/ journal.pone.0007302.
27. Przetak M, et al. 2003. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine 21:961-970. (Pubitemid 36126431)
28. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. 2008. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180:5402-5412.
29. Yip HC, et al. 1999. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162:3942-3949.